مجله دانشکده پزشکی اصفهان
پیاپی 606 (هفته دوم اسفند 1399)

Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic disease that is related to ovarian stimulation by assisted reproduction technology and other infertility treatments. The aim of this study was to determine the effect of GnRH antagonist and cabergoline (Dostinx) on the treatment of ovarian hyperstimulation syndrome in women exposed to this syndrome.

In this quasi-experimental study conducted in Shahid Beheshti hospital in Isfahan, Iran, in 2020, 30 infertile women treated with in vitro fertilization (IVF) were randomly divided into two groups; the first group was treated with steroids and the second group with cabergoline. Age, body mass index, total dose of prescribed gonadotropin, number of oocytes and estradiol level, length of hospital stay, and severity of ovarian hyperstimulation symptoms were determined and compared between the group.

The frequency of ovarian hyperstimulation syndrome in each group was 2 cases (13.33%). Besides, the amount of injected gonadotropin, number of eggs removed, estradiol level, length of hospital stay and paracentesis were not significantly different between the two groups (P > 0.050 for all).

According to the results of the present study, the effect of cabergoline and cetrotide in preventing the occurrence and severity of ovarian hyperstimulation syndrome, length of hospital staying, and the need for paracentesis are similar, and there is no preference in using any of these drugs.

Non-alcoholic fatty liver disease includes a spectrum of clinical syndromes from early steatosis to liver cirrhosis. Therefore, the aim of the present study was to investigate the effects of exercise training with silymarin supplementation on liver enzymes and weight of male fatty liver rats.

In this study, 40 adult male Wistar rats weighing 159 ± 3 g were randomly divided into 5 equal groups of normal diet/saline, high-fat diet/saline, high-fat diet/silymarin supplement, high-fat diet/training/ saline, and high-fat diet/training/supplement. Modeling of fatty liver with high-fat diet containing 45% energy from carbohydrates, 41% fat, and 14% protein was performed at a daily dose of 10 g per 100 g of body weight; the control group had a normal diet. The training groups practiced intermittently for 8 weeks (5 sessions per week, each session lasting 30 minutes) at intensity close to VO2max. Silymarin and saline supplementation was gavaged as 140 mg daily per kg body weight for 2 weeks. Liver tissue sampling was performed 72 hours after exercise to evaluate liver enzymes. Data were analyzed using one-way analysis of variance and Tukey post hoc test (P <0.05).

Liver alanine transaminase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) enzymes significantly reduced in the periodic training and periodic exercise/silymarin supplement groups compared to the control group; but no significant difference was observed in silymarin supplement groups compared to the control group.

Use of silymarin supplement with exercise, especially intermittent and high-intensity exercise, can modulate inflammatory and oxidative responses, and can be a suitable method to treat patients with non-alcoholic fatty liver disease.

Due to the importance of controlling recurrence of colorectal cancer, the effect of serum lipid profile and the fatty acid composition of cancer cell membranes on the response to treatment and survival, and the lack of clinical study on the effect of conjugated linoleic acid supplementation (CLA) in these patients, this study investigated the effect of CLA supplementation on serum fatty acid pattern, lipid profiles, and carcinoembryonic antigen (CEA) tumor marker in patients with rectal cancer treated with preoperative chemotherapy.

In this randomized double-blind placebo-controlled pilot study, 31 patients with rectal cancer undergoing chemoradiotherapy assigned into the CLA group (n = 15), receiving 3 g CLA/d, and placebo group (n = 16) receiving placebo capsules for 6 weeks. Before and after intervention, serum fatty acid pattern, triglyceride, cholesterol, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), and CEA were evaluated.

In placebo group, CLA supplementation increased the percentage of serum CLA (P = 0.35). CLA supplementation increased alpha linolenic acid (P = 0.01) significantly, and decreased the total omega-6 fatty acids and the omega-6 to omega-3 ratio. As compare with placebo, CLA supplementation had no significant effect on lipid profiles (P > 0.05).

Considering the positive effects of CLA on omega-3 fatty acids, and to our knowledge, this is the first study that assess the effect of CLA supplementation; further studies with larger sample size are needed to generalize findings of this study.